DUBLIN–(BUSINESS WIRE)–The “Molecular Diagnostics for Cancer: Markets Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides and Impact of Artificial Intelligence” report has been added to ResearchAndMarkets.com’s offering.
The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report. The report includes five year market forecasts.
Cancer Molecular Diagnostics is back on the growth path. And growth is accelerating in every segment. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. Over 140 companies are profiled. A range of dynamic trends are pushing market growth and company valuations.
Exciting technical developments especially in companion diagnostics, hold the promise of a dynamic, growing and evolving world market where single laboratories serve a global patient base.
Molecular Diagnostics for Cancer provides data that analysts and planners can use. Hundreds of pages of information including a complete list of Current United States Medicare Fee Payment Schedules to help understand test pricing in detail. Make facilities planning decisions. Forecast demand for new testing regimes or technologies. Make research investment decisions.
Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.
Key Market Trends
- Personalized medicine
- Pharmacogenomics
- Liquid biopsy
- Minimal residual disease testing
- Emergence of new economies with large markets
- Physician diagnostics being displaced by new intelligent diagnostic tests
Key Topics Covered:
1 Market Guides
1.1 Cancer MDx – Strategic Situation Analysis
1.2 Guide for Executives, Marketing, and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors
1.4 Impact of Artificial Intelligence on Cancer MDx
2 Introduction and Market Definition
2.1 What are Molecular Diagnostics?
2.2 The Diagnostics Revolution
2.3 Market Definition
2.3.1 Revenue Market Size
2.4 Methodology
2.4.1 Methodology
2.4.2 Sources
2.4.3 Authors
2.5 Perspective: Healthcare Spending
2.5.1 Global Healthcare Spending
2.5.2 Spending on Healthcare and Pharmaceuticals
2.5.3 Spending on Diagnostics
2.5.4 Important Role of Insurance for Medical Services
3 Market Overview
3.1 Market Segments
3.1.1 Traditional Market Segmentation
3.1.2 Laboratory Focus and Segmentation
3.2 Industry Structure
3.2.1 Hospital Testing Share
3.2.2 Economies of Scale
3.2.3 Physician Office Labs
3.2.4 Physician’s and POCT
4 Market Trends
4.1 Factors Driving Growth
4.1.1 New Diagnostics Create New Markets
4.1.2 New Roles for Diagnostics
4.1.3 Aging Effect
4.1.4 Expanding the Pharmaceutical Toolbox
4.1.5 Regulatory Retreat
4.2 Factors Limiting Growth
4.2.1 Falling Prices
4.2.2 Lower Costs
4.2.3 Wellness has a Downside
4.3 Instrumentation, Automation and Diagnostic Trends
4.3.1 Traditional Automation and Centralization
4.3.2 The New Automation, Decentralization and Point Of Care
4.3.3 Instruments Key to Market Share
4.3.4 Bioinformatics Plays a Role
4.3.5 PCR Takes Command
4.3.6 Next Generation Sequencing Fuels a Revolution
4.3.7 NGS Impact on Pricing
4.3.8 Whole Genome Sequencing, A Brave New World
4.3.9 Companion Diagnostics Blurs Diagnosis and Treatment
4.3.10 Shifting Role of Diagnostics
4.3.11 Multiplexing and Foundation One
4.3.12 Pharmacogenomics Technology
4.3.13 Gene Editing and Gene Therapy
5 Molecular Diagnostics Recent Developments
5.1 Recent Developments – Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Biodesix Revenues up
5.3 Waters to buy Becton unit
5.4 QuidelOrtho refocuses with LEX acquisition
5.5 Guardant Health Guardant360 Tissue
5.6 AccuStem Sciences & EmeritusDx partner for Lung Cancer Screening
5.7 LetsGetChecked Launches Hereditary Cancer Test
5.8 Guardant Health’s Colorectal Test New Status
5.9 Tempus xT CDx
5.10 OneCell Diagnostics Raises $16M
5.11 A. Menarini to use Nucleix Bladder Cancer Test
5.12 Foundation Medicine, Repare Therapeutics to Develop CDx
5.13 NHS Declines to Accelerate Grail Galleri Implementation
5.14 GeneDx Sees Growing Demand for Testing
5.15 Thermo Fisher and Bayer to Develop CDx for Cancer Therapies
5.16 ClearNote Health Expands Into Immunotherapy Monitoring
5.17 Foundation Medicine to Collaborate on CDx for Lung Cancer
5.18 Qiagen and Myriad Genetics Partner to Develop Cancer CDx
5.19 Lung Cancer Data Heralds Shift for Hummingbird Dx
5.20 PamGene Awarded €7.5M for Immunotherapy Test
5.21 Grail Cancer Test Faces New Clinical Questions
5.22 Freenome Acquires Cancer Dx Firm Oncimmune
5.23 Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology
5.24 Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients
5.25 Digital Pathology Meets Cancer Sequencing
5.26 Exact Sciences Preps Expanded Oncology Portfolio
5.27 Qiagen Details Oncology Plans for Digital PCR Platform
5.28 Sema4 Exiting Reproductive Health Screening
5.29 Thermo Fisher Introduces Cancer Profiling Assay
5.30 Genomic Test IDs Cysts Likely to Progress to Cancer
5.31 Naveris to Commercialize Virus-Related Cancer Tests
5.32 Larger Liquid Biopsy Panels Loom
5.33 Halo Diagnostics to Offer Genomic Profiling Tests
5.34 BillionToOne Raises $125M
5.35 Local Cancer Genomic Profiling Options Grow
5.36 German MDx Firm Mainz Biomed Raises $10M in IPO
5.37 Guardant Health Q3 Revenues Up 27 Percent
5.38 BforCure Raises $2.3M to Adapt Rapid PCR Platform for Cancer Detection
5.39 Nucleix to Invest in Early-Stage Lung Cancer Dx
5.40 Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics
5.41 Grail Gets Approval for Galleri Multicancer Test
5.42 Finnish Firms to Form Point-of-Care Testing Firm
5.43 Datar Cancer Genetics Expands to Dx and Screening
5.44 HTG Molecular Diagnostics: HTG Transcriptome Panel
5.45 PacBio’s Omniome Acquisition Shortens Path to Clinical
5.46 Invitae to Acquire Genosity for $200M
5.47 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
5.48 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
5.49 Natera Revenues Grow 35 Percent
5.50 AnchorDx Closes $40M Financing Round
5.51 Exact Sciences Strategy for End-to-End Cancer Testing
5.52 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch
6 Profiles of Key MDx Companies
6.1 10x Genomics, Inc.
6.2 Abbott Laboratories
6.3 AccuraGen Inc.
6.4 Acuamark Diagnostics
6.5 Adaptive Biotechnologies
6.6 Admera Health, LLC
6.7 Aethlon Medical
6.8 Agilent
6.9 Amoy Diagnostics Co., Ltd.
6.10 Anchor Dx
6.11 ANGLE plc
6.12 ARUP Laboratories
6.13 AVIVA Systems Biology
6.14 Baylor Miraca Genetics Laboratories
6.15 Beckman Coulter Diagnostics (Danaher)
6.16 Becton, Dickinson and Company
6.17 BGI Genomics Co. Ltd
6.18 BillionToOne
6.19 Bioarray Genetics
6.20 Biocartis
6.21 Biocept, Inc.
6.22 Biodesix Inc.
6.23 BioFluidica
6.24 BioGenex
6.25 BioIVT
6.26 Biolidics Ltd
6.27 bioMerieux Diagnostics
6.28 Bioneer Corporation
6.29 Bio-Rad Laboratories, Inc
6.30 Bio-Reference Laboratories
6.31 Bio-Techne
6.32 Bioview
6.33 Bristol-Myers Squibb
6.34 Burning Rock
6.35 C2i Genomics
6.36 Cardiff Oncology
6.37 Caris Molecular Diagnostics
6.38 Castle Biosciences, Inc.
6.39 Celemics
6.40 CellCarta
6.41 CellMax Life
6.42 Cepheid (Danaher)
6.43 Charles River Laboratories
6.44 Circulogene
6.45 Cizzle Biotech
6.46 Clearbridge Biomedics
6.47 Clinical Genomics
6.48 Cytolumina Technologies Corp.
6.49 Datar Cancer Genetics Limited
6.50 Diagnologix LLC
6.51 Diasorin S.p.A.
6.52 Dxcover
6.53 Element Biosciences
6.54 Enzo Biochem
6.55 Epic Sciences
6.56 Epigenomics AG
6.57 Erythra
6.58 Eurofins Scientific
6.59 Exact Sciences
6.60 Fabric Genomics
6.61 Fluxion Biosciences (Cell Microsystems)
6.62 Freenome
6.63 FUJIFILM Wako Diagnostics
6.64 Fujirebio
6.65 Fulgent Genetics
6.66 Fyr Diagnostics
6.67 GeneDx Holdings
6.68 GeneFirst Ltd.
6.69 Genetron Holdings
6.70 GenomOncology
6.71 GILUPI Nanomedizin
6.72 Guardant Health
6.73 HansaBiomed
6.74 HTG Molecular Diagnostics
6.75 iCellate
6.76 ICON PLC
6.77 Illumina
6.78 Incell Dx
6.79 Inivata
6.80 INOVIQ
6.81 Invitae Corporation
6.82 Invivogen
6.83 Invivoscribe
6.84 J&J Innovative Medicine
6.85 Lucence Health
6.86 Lucid Diagnostics
6.87 Lunglife AI Inc
6.88 MDNA Life SCIENCES, Inc.
6.89 MDx Health
6.90 Menarini Silicon Biosystems
6.91 Mesa Laboratories, Inc.
6.92 Metabiomics Corp
6.93 Millipore Sigma
6.94 Miltenyi Biotec
6.95 miR Scientific
6.96 Myriad Genetics
6.97 Nanostring
6.98 NantHealth, Inc.
6.99 Natera
6.100 NeoGenomics
6.101 NGeneBio
6.102 Novogene
6.103 Oncimmune
6.104 Oncocyte
6.105 OncoDNA
6.106 Oncohost
6.107 OraLiva
6.108 Oxford Nanopore Technologies
6.109 PamGene
6.110 Panagene
6.111 Personalis
6.112 Perthera
6.113 PGDx (Labcorp)
6.114 Precipio
6.115 PrecisionMed
6.116 Predicine
6.117 Predictive Oncology
6.118 Prenetics
6.119 Promega
6.120 Qiagen
6.121 QuidelOrtho
6.122 Rarecells SAS
6.123 RareCyte
6.124 Revvity
6.125 Roche Diagnostics
6.126 S2 Genomics
6.127 Screencell
6.128 Sherlock Biosciences
6.129 Siemens Healthineers
6.130 simfo GmbH
6.131 Singlera Genomics Inc.
6.132 Singular Genomics
6.133 Singulomics
6.134 SkylineDx
6.135 Standard BioTools
6.136 Stemcell Technologies
6.137 Stilla Technologies
6.138 Sysmex Inostics
6.139 Tempus Labs, Inc.
6.140 Thermo Fisher Scientific
6.141 Todos Medical
6.142 Ultima Genomics
6.143 Variantyx
6.144 Vela Diagnostics
6.145 Veracyte
6.146 VolitionRX
6.147 Vortex Biosciences
6.148 Zhejiang Orient Gene Biotech
7 The Global Market for MDx Cancer
7.1 MDx Cancer – Global Market Overview by Country
7.2 Global Market by Cancer Type – Overview
7.3 Global Market by Product Type – Overview
7.4 Global Market by Place – Overview
8 Global Market by Cancer Type
8.1 MDx Breast Cancer
8.2 MDx Colorectal Cancer
8.3 MDx Cervical Cancer
8.4 MDx Lung Cancer
8.5 MDx Prostate
8.6 MDx Melanoma Cancer
8.7 MDx Blood
8.8 MDx Companion Dx Development
8.9 MDx Other Cancer
9 Global Market by Product Type
9.1 MDx Instruments
9.2 MDx Reagents
9.3 MDx Software and Services
10 Global Market by Place
10.1 MDx Clinical Laboratory
10.2 MDx Pharmaceutical
10.3 MDx Research
11 Cancer Treatment and Trials
11.1 FDA Approvals by Year and Application
11.2 Clinical Trials Starts
11.3 Prevalence of Cancer Treatments
12 Appendices
12.1 United States Medicare System: Clinical Laboratory Fees Schedule
12.2 The Most Used IVD Assays
12.3 The Highest Grossing Assays
12.4 FDA-Approved Human Genetic Tests
12.5 FDA Approved Pharmacogenomics Tests
For more information about this report visit https://www.researchandmarkets.com/r/ex36gq
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
